Selected Cancer Drugs and Indications
Appendix 3: Selected Cancer Drugs and Indications
Newly approved or newly labeled by the US Food and Drug Administration (FDA), 2014
FDA Approvals
January 2014
Dabrafenib (Tafinlar)-for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Trametinib (Mekinist)-for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
February 2014
Ibrutinib (Imbruvica)-for the treatment of chronic lymphocytic leukemia.
April 2014
Ceritinib (Zykadia)-for the treatment of anaplastic lymphoma kinase–positive, metastatic non–small-cell lung cancer.
Mercaptopurine (Purixan)-for the treatment of acute lymphoblastic leukemia.
Ofatumumab (Arzerra)-for the treatment of chronic lymphocytic leukemia.
Ramucirumab (Cyramza)-for the treatment of metastatic, gastric or gastroesophageal junction adenocarcinoma.
Siltuximab (Sylvant)-for the treatment of multicentric Castleman disease.
July 2014
Belinostat (Beleodaq)-for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Idelalisib (Zydelig)-for the treatment of relapsed chronic lymphocytic leukemia.
August 2014
Bevacizumab (Avastin)-for the treatment of persistent, recurrent or metastatic cervical cancer.
September 2014
Pembrolizumab (Keytruda) for the treatment of unresectable or metastatic melanoma.
For additional information and an up-to-date listing of newly approved oncology drugs, visit the FDA’s website.
